December 19, 2025 06:25 am (IST)
Follow us:
facebook-white sharing button
twitter-white sharing button
instagram-white sharing button
youtube-white sharing button
‘Worst is over,’ says IndiGo CEO after flight chaos; staff told to ignore speculation | Chaos at Hyderabad's Lulu Mall! Nidhhi Agerwal swarmed by fans, police register case | TCS bets big on AI, shares spike as company reveals ambitious plan | Delhi goes into emergency mode! Work from home, vehicle bans as AQI hits ‘severe’ | Massive fire guts shanties near Eco Park in Kolkata; no casualties | Indian Visa Application Centre in Dhaka shuts down early amid rising security concerns | Market update: Sensex tumbles 120 points, Nifty below 25,850 at closing bell | ‘Won’t apologise’: Prithviraj Chavan stands firm on controversial Operation Sindoor remark despite backlash | India summons Bangladesh High Commissioner after provocative 'seven sisters' remark | Amazon eyes $10 billion investment in OpenAI — a gamechanger for AI industry!
AstraZeneca
Pixabay

AstraZeneca's COVID-19 vaccine trial to resume in US

| @indiablooms | Oct 24, 2020, at 03:28 pm

Washington/Xinhua: Multinational pharmaceutical company AstraZeneca said on Friday it will resume the trial of its experimental COVID-19 vaccine in the United States, which has been paused since September.

The company said the U.S. Food and Drug Administration (FDA) authorized the restart of the trial in the United States on Friday, following the resumption of trials in other countries in recent weeks.

The FDA reviewed all safety data from trials globally and concluded it was safe to resume the trial, said the company in a statement.

As part of the standard review process for trial safety events, a voluntary pause to vaccination across all global trials was triggered on Sept. 6 to allow the examination of safety data by independent monitoring committees, according to the company.

The recommendations from these reviews have been supported by international regulators, who also confirmed that the trials were safe to resume, said the statement.

AstraZeneca said results from the late-stage trials are expected later this year.  

Support Our Journalism

We cannot do without you.. your contribution supports unbiased journalism

IBNS is not driven by any ism- not wokeism, not racism, not skewed secularism, not hyper right-wing or left liberal ideals, nor by any hardline religious beliefs or hyper nationalism. We want to serve you good old objective news, as they are. We do not judge or preach. We let people decide for themselves. We only try to present factual and well-sourced news.

Support objective journalism for a small contribution.